Related Experiment Videos
Neurofibromatosis type 2 appears to be a genetically homogeneous disease
S A Narod1, D M Parry, J Parboosingh
1McGill Centre for Human Genetics, Montreal, Quebec, Canada.
American Journal of Human Genetics
|September 1, 1992
Summary
Neurofibromatosis type 2 (NF2) is linked to chromosome 22, not chromosome 17. Genetic markers on chromosome 22 can now aid in presymptomatic diagnosis for NF2 families.
Area of Science:
- Genetics
- Oncology
- Neurology
Background:
- Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder.
- NF2 is characterized by tumors of the nervous system, primarily vestibular schwannomas.
- NF2 is clinically distinct from neurofibromatosis type 1 (NF1).
Purpose of the Study:
- To precisely map the gene responsible for NF2.
- To investigate potential additional susceptibility loci for NF2.
- To confirm the chromosomal location of the NF2 gene.
Main Methods:
- Linkage analysis was performed on 12 NF2 families.
- Four polymorphic markers from chromosome 22 were used.
- A marker at the NF1 locus on chromosome 17 was also utilized.
Main Results:
- The gene for NF2 was confirmed to be on chromosome 22.
- Results did not support the hypothesis of genetic heterogeneity in NF2.
- The NF2 gene is tightly linked to the D22S32 locus.
- The CRYB2 locus marker was informative but requires cautious interpretation due to recombination.
Conclusions:
- Chromosome 22 markers are valuable for presymptomatic diagnosis in NF2.
- The findings refine the genetic understanding of NF2.
- Further research may utilize these markers for improved diagnostic accuracy.